Navigation Links
YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
Date:2/13/2009

.3 million for the first six months of fiscal 2009 compared with $4.1 million for the first six months of fiscal 2008.

Licensing and product development expenses were $4.4 million for the second quarter of fiscal 2009 compared with $4.2 million for the second quarter of fiscal 2008. Licensing and product development expenses were $8.3 million for the first six months of fiscal 2009 compared with $7.8 million for the first six months of fiscal 2008.

Costs associated with development activities for nimotuzumab increased by $1.2 million to $2.2 million and by $1.3 million to $3.3 million for the three and six months ended December 31, 2008 respectively, compared to the same periods in the prior year. The increase in expenses is related to preparation for the two new clinical trials and final payments for the trial in colorectal cancer.

Costs associated with development activities for AeroLEF(TM) decreased by $0.2 million to $0.6 million for the three month period ended December 31, 2008 compared to the same period in the prior year. For the six month period ended December 31, 2008 costs were $1.1 million, similar to the same period in the prior year.

Net loss for the second quarter of fiscal 2009 was $3.2 million ($0.06 per share) compared to $4.5 million ($0.08 per share) for the same period last year. Net loss for the first six months of fiscal 2009 was $6.3 million ($0.11 per share) compared to $8.1 million ($0.15 per share) for the same period last year.

As at December 31, 2008 the Company had cash and cash equivalents and short-term deposits totaling $50.1 million and payables and accrued liabilities totaling $2.1 million compared to $58.1 million and $2.0 million respectively at June 30, 2008.

As at December 31, 2008 the Company had 58,216,309 common shares outstanding, of which 2,380,953 common shares are held in escrow to be released contingent upon the completion of certain milestones.

About YM B
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
2. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
3. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
5. BD Biosciences to Distribute FCS Express
6. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
7. Cell Biosciences Introduces Kits for Oncoprotein Analysis
8. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
9. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June ... of the Adult Stem Cell Technology Center, LLC ( ... under appreciated unique property of adult tissue stem cells. ... Misunderstood in the Past, Important for the Future,” embodied ... He gave the address at the 4th World Congress ...
(Date:12/24/2014)... On Friday, December 19, 2014, ... Omnibus and Continuing Resolution Appropriations Act of 2015, ... condition eligible to receive funding through the Congressionally ... Department of Defense (DoD). The Hydrocephalus Association (HA), ... Hill, is celebrating this victory for the over ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... on methyl mercaptan such as its definition, ... also presents product specification, manufacturing process, and ... regions, technology and applications. The analysis also ... survey, marketing channels, industry development trend and ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... Oct. 18 /PRNewswire / -- Fate ... human induced pluripotent stem cells (iPSCs) using a combination ... efficiency of reprogramming. The discoveries, which were made ... Fate Therapeutics and The Scripps Research Institute (TSRI), represent ...
... Holdings, Inc. ("Cellu Tissue") today announced that it has filed a ... Commission (the "SEC") relating to a proposed initial public offering of ... shares to be sold by Cellu Tissue and shares to be ... shares to be offered, the allocation of shares to be sold ...
... , BLACKSBURG, Va., Oct. 16 Harold "Skip" Garner ... Institute (VBI) at Virginia Tech. Garner joins VBI from ... he was professor of Biochemistry and Internal Medicine and ... Developmental Biology. Before coming to UTSW in 1994, Garner ...
Cached Biology Technology:Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 2Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 3Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock 2Garner to Lead Virginia Bioinformatics Institute 2Garner to Lead Virginia Bioinformatics Institute 3
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... addition of the "iPhone 5S Fingerprint Sensor ... report to their offering. ... acquisition of AuthenTec in July 2012, Apple introduced ... It is currently the only device of Apple ...
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... selection at the single-gene level have a powerful new ... in molecular and computational biology in the USC College ... sought to replace the standard neutral model, a common ... method based on hard genomic data. , The group's ...
... by scientists at the Broad Institute of MIT and ... extensive library of molecular reagents to silence most human ... 24 issue of Cell, this library consists of small ... the user to dissect the genetic underpinnings of normal ...
... many years debated the cause of the Plague of ... using DNA collected from teeth from an ancient Greek ... responsible for this devastating epidemic. The study appears on ... Diseases (IJID) published by Elsevier on behalf of the ...
Cached Biology News:Natural selection at single gene demonstrated 2New RNAi tools enable systematic studies of gene function 2New RNAi tools enable systematic studies of gene function 3Typhoid fever led to the fall of Athens 2
... known as ChemiArrayTM Mouse Cytokine Antibody ... current methodologies. Besides the ability to ... a more accurate reflection of active ... secreted cytokines, and no amplification step ...
... DNA Engine instrument is the cycler ... Unprecedented thermal uniformity and swappable blocks ... This rugged machine is ... a platform for new features and ...
... (MSTA) slides were designed to study protein expression ... species. Tissue slices from three different species ... then be treated as a single histological slide ... hybridization. This format allows a rapid ...
... Multiple Species Tissue Array (MSTA) slides were designed ... and tissues from multiple species. Tissue slices ... MSTA slide which can then be treated as ... or in situ hybridization. This ...
Biology Products: